Trial · NCT01922011
Results by group57
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 57
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
Percentage of Participants With Clinical Improvement in the 3 General Categories of Pain, Inflammation, and Limb Function Based on the Investigator's Overall Assessment of Severity of Each of the Symptom Categories. | Daptomycin | 77.5 | 95% Confidence Interval 67.7 to 87.2 | Percentage of participants | |
Percentage of Participants With Clinical Improvement in the 3 General Categories of Pain, Inflammation, and Limb Function Based on the Investigator's Overall Assessment of Severity of Each of the Symptom Categories. | Vancomycin or Nafcillin | 82.9 | 95% Confidence Interval 74.0 to 91.7 | Percentage of participants | |
| Percentage of Participants With Clinical Improvement Measured as a Composite End Point of Pain, Inflammation, Limb Function, Body Temperature, and C-reactive Protein at End-of IV (EOIV) Therapy Visit. | Daptomycin | 71.0 | 95% Confidence Interval 60.3 to 81.7 | Percentage of participants | |
| Percentage of Participants With Clinical Improvement Measured as a Composite End Point of Pain, Inflammation, Limb Function, Body Temperature, and C-reactive Protein at End-of IV (EOIV) Therapy Visit. | Vancomycin or Nafcillin | 76.5 | 95% Confidence Interval 66.4 to 86.6 | Percentage of participants | |
| Percentage of Participants With a Favorable Clinical Outcome | Daptomycin | At End of IV (EOIV) Therapy (n= 71,69) | 85.9 | 95% Confidence Interval 77.8 to 94.0 | Percentage of participants |
| Percentage of Participants With a Favorable Clinical Outcome | Vancomycin or Nafcillin | At End of IV (EOIV) Therapy (n= 71,69) | 91.3 | 95% Confidence Interval 84.7 to 98.0 | Percentage of participants |
| Percentage of Participants With a Favorable Clinical Outcome | Daptomycin | At End of Therapy (EOT) (n= 71,69) | 83.1 | 95% Confidence Interval 74.4 to 91.8 | Percentage of participants |
| Percentage of Participants With a Favorable Clinical Outcome | Vancomycin or Nafcillin | At End of Therapy (EOT) (n= 71,69) | 89.9 | 95% Confidence Interval 82.7 to 97.0 | Percentage of participants |
| Percentage of Participants With a Favorable Clinical Outcome | Daptomycin | At Test Of Cure (TOC) (n= 71,70) | 81.7 | 95% Confidence Interval 72.7 to 90.7 | Percentage of participants |
| Percentage of Participants With a Favorable Clinical Outcome | Vancomycin or Nafcillin | At Test Of Cure (TOC) (n= 71,70) | 87.1 | 95% Confidence Interval 79.3 to 95.0 | Percentage of participants |
| Percentage of Participants With a Clinical Cure Categorized by Baseline Pathogen at Test of Cure | Daptomycin | Overall Baseline Infecting Pathogen (n =45,47) | 77.8 | 95% Confidence Interval 65.6 to 89.9 | Percentage of participants |
| Percentage of Participants With a Clinical Cure Categorized by Baseline Pathogen at Test of Cure | Vancomycin or Nafcillin | Overall Baseline Infecting Pathogen (n =45,47) | 87.2 | 95% Confidence Interval 77.7 to 96.8 | Percentage of participants |
| Percentage of Participants With a Clinical Cure Categorized by Baseline Pathogen at Test of Cure | Daptomycin | Staphylococcus Aureus (SA) (n= 43,42) | 76.7 | 95% Confidence Interval 64.1 to 89.4 | Percentage of participants |
| Percentage of Participants With a Clinical Cure Categorized by Baseline Pathogen at Test of Cure | Vancomycin or Nafcillin | Staphylococcus Aureus (SA) (n= 43,42) | 88.1 | 95% Confidence Interval 78.3 to 97.9 | Percentage of participants |
| Percentage of Participants With a Clinical Cure Categorized by Baseline Pathogen at Test of Cure | Daptomycin | Methicillin Susceptible SA (MSSA) (n= 39,37) | 79.5 | 95% Confidence Interval 66.8 to 92.2 | Percentage of participants |
| Percentage of Participants With a Clinical Cure Categorized by Baseline Pathogen at Test of Cure | Vancomycin or Nafcillin | Methicillin Susceptible SA (MSSA) (n= 39,37) | 94.6 | 95% Confidence Interval 87.3 to 100 | Percentage of participants |
| Percentage of Participants With a Clinical Cure Categorized by Baseline Pathogen at Test of Cure | Daptomycin | Methicillin Resistant SA (MRSA) (n= 4,4) | 50.0 | 95% Confidence Interval 1.0 to 99.0 | Percentage of participants |
| Percentage of Participants With a Clinical Cure Categorized by Baseline Pathogen at Test of Cure | Vancomycin or Nafcillin | Methicillin Resistant SA (MRSA) (n= 4,4) | 25.0 | 95% Confidence Interval 0.0 to 67.4 | Percentage of participants |
| Percentage of Participants With a Clinical Cure Categorized by Baseline Pathogen at Test of Cure | Daptomycin | Other Pathogens (n= 2,7) | 100 | 95% Confidence Interval 100 to 100 | Percentage of participants |
| Percentage of Participants With a Clinical Cure Categorized by Baseline Pathogen at Test of Cure | Vancomycin or Nafcillin | Other Pathogens (n= 2,7) | 85.7 | 95% Confidence Interval 59.8 to 100 | Percentage of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01922011/results